12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Piromelatine: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 120 patients with primary insomnia showed that once-daily 20 and 50 mg doses of piromelatine for 4 weeks each met the secondary endpoint of improving the duration of WASO at the first 2 nights of treatment vs. placebo (p=0.02 for both). Both doses of piromelatine also significantly improved the duration...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >